GlassScriptPhysician profile
Bridget Eileen Forsmark
NPI 1891021945
$2,011.84
in general payments reported to CMS, 2019-2025
24 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $531 · 2022: $252 · 2023: $531 · 2024: $306 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $326.81 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $284.89 | 2021-2023 | |
| Pfizer INC. | $189.54 | 2023-2025 | |
| Amgen INC. | $180.10 | 2023-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.55 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $112.15 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $93.25 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $79.99 | 2021-2025 | Nexium |
| Lilly USA, LLC | $74.23 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $71.69 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $69.75 | 2021-2025 | Ozempic |
| Astellas Pharma US INC | $59.09 | 2021 | |
| Amneal Pharmaceuticals LLC | $50.49 | 2022-2025 | Rytary, Unithroid |
| Merck Sharp & Dohme LLC | $32.60 | 2021 | |
| Inogen, INC. | $29.01 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $25.47 | 2022 | |
| Esperion Therapeutics, INC. | $24.00 | 2021 | |
| Clarus Therapeutics INC. | $23.09 | 2021 | |
| Axsome Therapeutics, INC. | $22.33 | 2025 | Symbravo |
| Nestle Healthcare Nutrition INC. | $22.13 | 2022 | |
| Radius Health, INC. | $20.04 | 2023 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.02 | 2024 | Xifaxan, Trulance |
| Seqirus USA INC | $14.08 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.54 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Forsmark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.